Cambrian Biopharma

Amplifier Therapeutics is a biopharmaceutical firm, developing AMP-activated protein kinase (AMPK) activator molecules to treat aging-related disorders such as metabolic problems, cardiovascular diseases, kidney diseases, and cancer.

Vita Therapeutics is a cell engineering company focused on developing innovative treatments for debilitating neuromuscular diseases and cancers. The company employs induced pluripotent stem cell (iPSC) technology to create specific cell types that can replace defective cells in patients. By targeting the underlying causes of these diseases, Vita Therapeutics aims to provide truly curative cellular medicines, offering new hope for individuals affected by these conditions.

Oviva Therapeutics is a movement to improve women's experience of aging through biomedical research, development and advocacy.

Vita Therapeutics is a cell engineering company focused on developing innovative treatments for debilitating neuromuscular diseases and cancers. The company employs induced pluripotent stem cell (iPSC) technology to create specific cell types that can replace defective cells in patients. By targeting the underlying causes of these diseases, Vita Therapeutics aims to provide truly curative cellular medicines, offering new hope for individuals affected by these conditions.

Sensei Biotherapeutics is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. The company is dedicated to developing precision cancer therapeutics that target tumor-specific antigens, focusing on next-generation cancer immunotherapies. Utilizing its proprietary ImmunoPhage platform, Sensei Biotherapeutics creates immune-activating agents designed to engage both innate and adaptive immune systems. The company's TMAb (Tumor Microenvironment Activated Biologics) platform aims to develop selective therapeutics that either disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Sensei Biotherapeutics is advancing four investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which are in various stages of development. The company brings together expertise in biology, immunology, and oncology, supported by a seasoned management team and scientific advisors, to address unmet needs in cancer treatment.

Sensei Biotherapeutics is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. The company is dedicated to developing precision cancer therapeutics that target tumor-specific antigens, focusing on next-generation cancer immunotherapies. Utilizing its proprietary ImmunoPhage platform, Sensei Biotherapeutics creates immune-activating agents designed to engage both innate and adaptive immune systems. The company's TMAb (Tumor Microenvironment Activated Biologics) platform aims to develop selective therapeutics that either disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Sensei Biotherapeutics is advancing four investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which are in various stages of development. The company brings together expertise in biology, immunology, and oncology, supported by a seasoned management team and scientific advisors, to address unmet needs in cancer treatment.

Samsara Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapies for age-related diseases and unmet medical needs. Founded in 2018 and headquartered in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique screening platform centered on geroprotectors to create caloric restriction mimetics (CRM) that target the core mechanisms of aging, such as proteostasis, autophagy, and energy metabolism. Samsara's research and development activities include the identification, chemical optimization, and in vivo validation of compounds that aim to extend healthy lifespan and address rare genetic and neurodegenerative disorders.